Literature DB >> 31792370

HLA-A*02:01 allele is associated with tanshinone-induced cutaneous drug reactions in Chinese population.

Qinyuan Zhu1, Yanzhou Zhang2, Jiekun Xuan3, Fanping Yang1, Binbin Du2, Sheng-An Chen1, Sijia Yan4, Menglin Jiang4, Huizhong Zhu4, Hao Xiong1, Xiaoqun Luo5, Qinghe Xing6.   

Abstract

Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying HLA-A*02:01 was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10-5; OR = 7.14, Pc = 8.00 × 10-6), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards HLA-A*02:01 (≤-7.5 kcal/mol). The result suggested HLA-A*02:01 may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31792370     DOI: 10.1038/s41397-019-0121-1

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  31 in total

1.  Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.

Authors:  Joo Hyun Lee; Yong-Jun Shin; Hye Jin Kim; Ju-Hee Oh; Young Pyo Jang; Young-Joo Lee
Journal:  Int J Pharm       Date:  2011-03-21       Impact factor: 5.875

Review 2.  Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.

Authors:  Limin Zhou; Zhong Zuo; Moses Sing Sum Chow
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

3.  Origin and evolution of China Pharmacopoeia and its implication for traditional medicines.

Authors:  Yun-Fang Hao; Jian-Guo Jiang
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

Review 4.  Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.

Authors:  Wenxing Chen; Yin Lu; Guangying Chen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

5.  Danshen and the Cardiovascular System: New Advances for an Old Remedy.

Authors:  Francesco Maione; Nicola Mascolo
Journal:  Semin Thromb Hemost       Date:  2016-03-07       Impact factor: 4.180

Review 6.  New developments in the chemistry and biology of the bioactive constituents of Tanshen.

Authors:  Xihong Wang; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2007-01       Impact factor: 12.944

Review 7.  Danshen diversity defeating dementia.

Authors:  Helmut M Hügel; Neale Jackson
Journal:  Bioorg Med Chem Lett       Date:  2013-12-18       Impact factor: 2.823

8.  Identification of major active constituents in the fingerprint of Salvia miltiorrhiza Bunge developed by high-speed counter-current chromatography.

Authors:  Ming Gu; Guifeng Zhang; Zhiguo Su; Fan Ouyang
Journal:  J Chromatogr A       Date:  2004-07-02       Impact factor: 4.759

Review 9.  Cardiovascular effects of Danshen.

Authors:  Tsung O Cheng
Journal:  Int J Cardiol       Date:  2007-03-23       Impact factor: 4.164

Review 10.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.